Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) EBITDA Margin: 2021-2022

Historic EBITDA Margin for Cardiol Therapeutics (CRDL) over the last 2 years, with Sep 2022 value amounting to 60.30%.

  • Cardiol Therapeutics' EBITDA Margin fell 3720.00% to 60.30% in Q3 2022 from the same period last year, while for Sep 2022 it was 20.32%, marking a year-over-year change of. This contributed to the annual value of -40,170.45% for FY2021, which is 4027021.00% down from last year.
  • Per Cardiol Therapeutics' latest filing, its EBITDA Margin stood at 60.30% for Q3 2022, which was down 14.21% from 70.29% recorded in Q2 2022.
  • In the past 5 years, Cardiol Therapeutics' EBITDA Margin ranged from a high of 102.14% in Q2 2021 and a low of -115.87% during Q1 2022.
  • Its 2-year average for EBITDA Margin is 51.62%, with a median of 70.29% in 2022.
  • Data for Cardiol Therapeutics' EBITDA Margin shows a maximum YoY plummeted of 21,509bps (in 2022) over the last 5 years.
  • Cardiol Therapeutics' EBITDA Margin (Quarterly) stood at 47.78% in 2021, then crashed by 3,720bps to 60.30% in 2022.
  • Its EBITDA Margin stands at 60.30% for Q3 2022, versus 70.29% for Q2 2022 and -115.87% for Q1 2022.